Is apixaban or rivaroxaban safe for use in breastfeeding women during the postnatal period based on infant exposure?
Physiologically based pharmacokinetic modeling suggests rivaroxaban, but not apixaban, may be safe during breastfeeding due to low infant exposure.
Our work demonstrates that apixaban would not be a suitable agent for breastfeeding women during the postnatal period, while rivaroxaban shows significant promise due to low infant exposure and warrants further investigation.
Butler et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: